Article
Dapagliflozin Ameliorates Myocardial Ischemia/Reperfusion Injury by Modulating EGFR Signaling and Targeting NCOA4-mediated Ferritinophagy
2024-10-17
Abstract excerpt
<title>Abstract</title> <p>SGLT2 inhibitor dapagliflozin (Dapa) has gained increasing attention in the treatment of myocardial ischemia-reperfusion injury (IRI). However, the mechanism of action of the cardiovascular benefits of Dapa is unclear. The present study aimed to investigate the effects of Dapa on myocardial IRI and the underlying molecular mechanisms. The effects of Dapa on myocardial IRI were investiga...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 28b5417b-b7e4-5377-ab80-a3378a5561ee
- DOI
- 10.21203/rs.3.rs-5172738/v1
